effects identified, and the conditions under which a chemical might cause those effects defined. The attempt to obtain emission-rate estimates might take the form of direct measurements, which are limited by the sensitivity of the measuring methods, the variability over time of emission rates, the cost of such measurements, and the inaccuracies affecting all such field work. Alternatively, similar measurements from other, comparable facilities might be used as bases to estimate emissions. The result is generally a list of chemicals with their expected average emission rates and sometimes a measure of the variability of the emission rates with time—for example, how short-term emission rates might differ from the long-term average. In many cases, there may be a list of the emission rates that are identified as maximums by the owner or operator of the facility.

After developing a list of chemicals identified as potentially of concern, a dose-response assessment is used to evaluate quantitatively the relation between exposures and toxic responses. Ideally, this assessment would consider all the particular conditions of exposure, including the complete mix of other potential contaminants from incineration, and exposures to the same and different chemicals from other sources. In practice, dose-response assessments are limited, by the regulatory milieu of most risk assessments, to the use of cancer potency-slope estimates or unit risks1 (for the evaluation of cancer risks) and reference doses2 (for the evaluation of noncancer risks) published in the Integrated Risk Information System (IRIS)3 or other regulatory documents by the Environmental Protection Agency (EPA) or the Agency for Toxic Substances and Disease Registry (ATSDR).

Most of the effort of individual risk assessments has gone into the evaluation of exposure, which is the third step in the risk-assessment paradigm. As discussed in Chapter 4, exposure assessment involves an estimation or measure-

1  

Cancer potency-slope estimates or unit risks. The human cancer potency-slope is the incremental increase in lifetime cancer risk per incremental unit of lifetime average dose (generally by ingestion, occasionally by other routes of exposure). The estimates of cancer potency-slope is obtained by assuming that the dose-response curve may be linear at low doses, and extrapolating to low dose from higher experimental doses. In many cases, there is an additional extrapolation from laboratory animals to humans. The unit risk is the incremental increase in lifetime cancer risk per incremental unit of air concentration of an airborne carcinogen. It is estimated using methods similar to those used for cancer potency-slope, but with slightly different assumptions adopted for inter-species extrapolation.

2  

The reference dose is a long-term average dose rate that is expected to result in no noncancer health effects in humans. It is obtained from experimental results in humans or animals by a relatively well-defined procedure that incorporates safety factors to account for all the defined extrapolations performed.

3  

IRIS. EPA's (1992b) Integrated Risk Information System (IRIS) is a database of human health effects that might result from exposure to various substances found in the environment. IRIS is accessible via the Internet at http://www.epa.gov//iris.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement